Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Rapid generation of drug-resistance alleles at endogenous loci using CRISPR-Cas9 indel mutagenesis.

PloS one - 1 Jan 2017

Ipsaro Jonathan J, Shen Chen, Arai Eri, Xu Yali, Kinney Justin B, Joshua-Tor Leemor, Vakoc Christopher R, Shi Junwei

Abstract excerpt

Genetic alterations conferring resistance to the effects of chemical inhibitors are valuable tools for validating on-target effects in cells. Unfortunately, for many therapeutic targets such alleles are not available. To address this issue, we evaluated whether CRISPR-Cas9-mediated insertion/deletion (indel) mutagenesis can produce drug-resistance alleles at endogenous loci. This method takes advantage of the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzimidazoles
Share to Clustered Regularly Interspaced Short Palindromic Repeats

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to CRISPR-Cas Systems

Share to Enhancer of Zeste Homolog 2 Protein

Share to Histone-Lysine N-Methyltransferase

Share to INDEL Mutation

Share to Methyltransferases

Share to Mutagenesis

Source

Open in PubMed Open full text

Identifiers

PMID: 28231254
DOI: 10.1371/journal.pone.0172177
PMCID: PMC5322889

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Rapid generation of drug-resistance alleles at endogenous loci using CRISPR-Cas9 indel mutagenesis.PMID 28231254Read ↗

A CRISPR Dropout Screen Identifies Genetic Vulnerabilities and Therapeutic Targets in Acute Myeloid LeukemiaSemantic proximity Read ↗

Epigenetic enzyme mutations as mediators of anti-cancer drug resistance.Semantic proximity Read ↗

Identifying chemogenetic interactions from CRISPR screens with drugZSemantic proximity Read ↗

A CRISPR-drug perturbational map for identifying new compounds to combine with commonly used chemotherapeuticsSemantic proximity Read ↗

Identifying chemogenetic interactions from CRISPR knockout screens with drugZSemantic proximity Read ↗

Repair of leukemia-associated single nucleotide variants via interallelic gene conversionSemantic proximity Read ↗

A CRISPR-drug perturbational map for identifying compounds to combine with commonly used chemotherapeuticsSemantic proximity Read ↗

Identification of novel genetic vulnerabilities and therapeutic targets in acute myeloid leukaemia using CRISPR dropout screensSemantic proximity Read ↗

Genome-wide CRISPR/Cas9 screen identifies etoposide response modulators associated with clinical outcomes in pediatric AMLSemantic proximity Read ↗

MLL partial tandem duplication leukemia cells are sensitive to small molecule DOT1L inhibitionSemantic proximity Read ↗

Combining CRISPR/Cas9 mutagenesis and a small-molecule inhibitor to probe the function of MELK in cancerSemantic proximity Read ↗

CRISPR-Cas9–mediated saturated mutagenesis screen predicts clinical drug resistance with improved accuracySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.